Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 234Thoracic 70Dermatologic 59Genitourinary 50Gastrointestinal 49Gynecologic 35Breast 33Sarcoma 11Other solid neoplasm 9Lymphoid 7CNS 2Plasma cell 1

Conditions

Multiple Myeloma 27Hodgkin Disease 3Breast Neoplasms 3Recurrence 2Ovarian Neoplasms 2Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Waldenstrom Macroglobulinemia 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myelomonocytic, Chronic 1

Interventions

pembrolizumab 1Vorinostat 1Thalidomide 1Rituximab 1Gemcitabine 1Fentanyl 1Docetaxel 1Capecitabine 1Bendamustine Hydrochloride 11-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b)pyrazin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × pembrolizumab × Plasma cell × Clear all
NCT04354246 2026-05-12

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Compugen Ltd

Phase 1 Completed
94 enrolled
GastrointestinalGynecologicHead & NeckPlasma cellThoracic

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Lung Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡